Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

Screening period: 45 days Double blind, double-dummy, primary analysis treatment period: 52 weeks Open label extended treatment period: minimum of 52 weeks due to a common study end of treatment date Follow up phone call: 30-37 days after end of treatment